Markets

Aspirin without the ulcers: PLx Pharma files for a $20 million IPO

A generic image of a pencil on a chart
Credit: Shutterstock photo

PLx Pharma, which is commercializing a delayed-release aspirin based on its proprietary lipid coating, filed on Monday with the SEC to raise up to $20 million in an initial public offering.

The company claims that its approved formulation of aspirin, PL2200 demonstrated a significant reduction in acute ulcers compared to immediate-release aspirin, and more reliable antiplatelet benefits than enteric aspirin. PLx Pharma also has a pipeline of other oral nonsteroidal anti-inflammatory drugs (NSAIDs) using its delivery system, including ibuprofen.

The Houston, TX-based company, which was founded in 2002, plans to list on the Nasdaq under the symbol PLXP. PLx Pharma initially filed confidentially on August 18, 2015. Maxim Group is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Aspirin without the ulcers: PLx Pharma files for a $20 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PLXP

Other Topics

IPOs

Latest Markets Videos